share_log

Needham Maintains Buy on Recursion Pharmaceuticals, Lowers Price Target to $16

Needham Maintains Buy on Recursion Pharmaceuticals, Lowers Price Target to $16

Needham維持對Recursion Pharmaceuticals買入評級,將價格目標下調至16美元
Benzinga ·  08/09 07:57  · 評級/大行評級

Needham analyst Gil Blum maintains Recursion Pharmaceuticals (NASDAQ:RXRX) with a Buy and lowers the price target from $17 to $16.

Needham分析師吉爾·布盧姆(Bil Blum)維持對Recursion Pharmaceuticals (納斯達克:RXRX)的買入評級,並將目標價格從$17降至$16。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論